halofuginone has been researched along with Multiple Myeloma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Hideshima, T; Jakubikova, J; Klippel, S; Leiba, A; Leiba, M; Mitsiades, CS; Nagler, A; Pines, M; Richardson, PG; Tai, YT | 1 |
1 trial(s) available for halofuginone and Multiple Myeloma
| Article | Year |
|---|---|
Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase; Humans; JNK Mitogen-Activated Protein Kinases; Male; Membrane Potential, Mitochondrial; Mice; Mice, SCID; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-bcl-2; Quinazolinones; Resting Phase, Cell Cycle; Tumor Suppressor Protein p53; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2012 |